

for hairpin ribozymes can be readily determined from the *Socs2* sequence. Certain appropriate sequences include, but are not limited to sequences used as targets for antisense molecules.--

**REMARKS**

**Restriction.**

In the October 3, 2001 Office Action the Examiner required restriction to one of the following groups under 35 U.S.C. §121:

- Group I: Claims 1-7 and 62-63, drawn to a nucleic acid that > encodes a gene product that when knocked out produces a high growth phenotype;
- Group II: Claims 8-22, and 27-36, drawn to a method of producing a knockout animal where the expression of *Socs-2* gene is inhibited;
- Group III: Claims 8, and 23-26, drawn to a knockout animal in which the expression of another gene, in addition to *Socs-2* has been inhibited;
- Group IV: Claims 37-46, 48, 59, and 60 drawn to a method of screening for an agent that alters a high growth phenotype using an in vitro cell culture system;
- Group V: Claims 37, 47, 48, and 61, drawn to a method of screening for an agent that alters a high growth phenotype using an animal;
- Group VI: Claims 48-55, and 58, drawn to a method of screening for an agent that interacts with a *Socs-2* nucleic acid in vitro and alters expression of a high growth phenotype;
- Group VII: Claims 48-53, and 56-58, drawn to a method of screening for an agent that interacts with a *Socs-2* protein in vitro and alters expression of a high growth phenotype;
- Group VIII: Claim 64, drawn to a polypeptide encoded by a certain polynucleotide;
- Group IX: Claim 65, drawn to an antibody that specifically binds to a certain polypeptide;
- Group X: Claims 66-71, drawn to a nucleic acid for disrupting a *Socs-2* gene; and
- Group XI: Claims 72-76, drawn to an animal cell in which the endogenous *Socs-2* has been disrupted.

**In response to this restriction requirement, Applicants elect Group II, claims 8-22, and 27-36.**

**Sequence Listing.**

This amendment is provided to comply with the Sequence Listing Rules, 37 C.F.R. §§ 1.821-1.825. A disk containing the sequence(s) in computer readable form, and a paper copy of the sequence information that has been printed from the floppy disk are provided herewith. The information contained in the computer readable disk was prepared through the use of the software program "PatentIn" and is identical to that of the paper copy.

The sequence listing introduces no new matter. The listing simply provides a formal copy of the sequences in the application as filed. The amendment to the specification also introduces no new matter. The amendment simply provides cross-reference numbers to the formal sequence listing.

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (510) 337-7871.

QUINE INTELLECTUAL PROPERTY LAW  
GROUP, P.C.  
P.O. BOX 458  
Alameda, CA 94501  
Tel: 510 337-7871  
Fax: 510 337-7877

Respectfully submitted,



Tom Hunter  
Reg. No: 38,498

**APPENDIX A**

**VERSION WITH MARKINGS TO SHOW CHANGES MADE IN 09/771,208 WITH ENTRY  
OF THIS AMENDMENT**

**In the specification:**

The sequence requirement for the hairpin ribozyme is any RNA sequence consisting of NNNBN\*GUCNNNNNN (where N\*G is the cleavage site, where B is any of G, C, or U, and where N is any of G, U, C, or A) (SEQ ID NO:[ 121 ]). Suitable *Socs2* recognition or target sequences for hairpin ribozymes can be readily determined from the *Socs2* sequence. Certain appropriate sequences include, but are not limited to sequences used as targets for antisense molecules.